=== PAGE 7 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Page 7

Payal Patel, PharmD
Bausch Health Companies Inc.
NDA 209354/MA 178 and 221

You are encouraged, but not required, to submit your response in eCTD format. All
correspondence submitted in response to this letter should be placed under eCTD Heading
1.15.1.6. Additionally, the response submission should be coded as an Amendment to eCTD
Sequence 5057 under NDA 209354. Questions related to the submission of your response
letter should be emailed to the OPDP RPM at CDER-OPDP-RPM@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Laurie Buonaccorsi, Pharm.D.
Regulatory Review Officer
Division of Advertising & Promotion Review 2
Office of Prescription Drug Promotion

{See appended electronic signature page}

Matthew J. Falter, Pharm.D.
Team Leader
Division of Advertising & Promotion Review 2
Office of Prescription Drug Promotion

Reference ID: 4961636
